Brilinta’s price cut 30%, Nexavar’s premium stays 1 year
By Kim, Jung-Ju | translator Alice Kang
21.11.22 06:00:52
가나다라
0
Entelon, with its reduced scope of reimbursement, voluntarily undergoes 2.6-2.9% price cut
Betmiga’s price, which had been fluctuating due to pricing lawsuits, will fall 23.6%
The insurance price of AstraZeneca Korea’s Brilinta tab. 90mg (ticagrelor) and Daxas tab. 500μg (roflumilast) will be reduced by 30% through the government’s ex-officio adjustment starting next month. On the other hand, the price of Bayer Korea’s Nexavar 200mg (sorafenib tosylate) will be maintained at its level for one more year.
The price of Hanlim Pharm’s Entelon, whose indications for blood circulation and ophthalmologic diseases survived the Pharmaceutical Benefit Adequacy Assessment, was voluntarily lowered by 2.6-2.9% for each dose.
According to the industry, the Ministry of Health and Welfare is working to apply the ‘Amendment to the drug reimbursement list and reimbursement c
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)